![Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study](https://www.j-stroke.org/upload//thumbnails/jos-2017-01578f1.gif)
Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study
![PDF] Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. | Semantic Scholar PDF] Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cbb09adedff6618050af35a8ddeb702029a0b2d6/5-Table1-1.png)
PDF] Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. | Semantic Scholar
![Stroke AHA/ASA on Twitter: "Check out the #VisualAbstract summarizing work in which authors showed that a lower dose of 0.6mg/kg alteplase is as effective as standard medical treatment in #stroke with unknown Stroke AHA/ASA on Twitter: "Check out the #VisualAbstract summarizing work in which authors showed that a lower dose of 0.6mg/kg alteplase is as effective as standard medical treatment in #stroke with unknown](https://pbs.twimg.com/media/EVHR37LUcAEF1OL.jpg:large)
Stroke AHA/ASA on Twitter: "Check out the #VisualAbstract summarizing work in which authors showed that a lower dose of 0.6mg/kg alteplase is as effective as standard medical treatment in #stroke with unknown
![Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review - Zhu - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review - Zhu - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c6c6d696-5c5f-4706-be44-e96f91a6955f/rth212795-gra-0004-m.jpg)
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review - Zhu - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
![Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial - The Lancet Neurology Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2064159794/2065870066/gr1.gif)
Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial - The Lancet Neurology
![Elsevier Hematology on Twitter: "(1/2) 1 in 10 acute ischemic stroke patients weighed 100 kg or more and thus were treated with the maximum dose of IV alteplase, but they did not Elsevier Hematology on Twitter: "(1/2) 1 in 10 acute ischemic stroke patients weighed 100 kg or more and thus were treated with the maximum dose of IV alteplase, but they did not](https://pbs.twimg.com/media/E6LL_n-XMAMt4tk.jpg:large)
Elsevier Hematology on Twitter: "(1/2) 1 in 10 acute ischemic stroke patients weighed 100 kg or more and thus were treated with the maximum dose of IV alteplase, but they did not
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/5584d24a-1666-42dc-9be9-55d76014e9f9/gr1.gif)
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology
![Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice | Stroke Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice | Stroke](https://www.ahajournals.org/cms/asset/c9b29dff-f0b6-4744-bee0-c28673b50586/strokeaha.122.038950.fig02.jpg)
Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice | Stroke
![PDF] Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study | Semantic Scholar PDF] Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fa7e45a71511d9a730802d3f6bf5cdeb95f7dcfe/6-Table3-1.png)
PDF] Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study | Semantic Scholar
![Indication, administration, and dosing of tissue plasminogen activators. | Download Scientific Diagram Indication, administration, and dosing of tissue plasminogen activators. | Download Scientific Diagram](https://www.researchgate.net/publication/330856346/figure/tbl1/AS:733895490281474@1551985728142/Indication-administration-and-dosing-of-tissue-plasminogen-activators_Q320.jpg)
Indication, administration, and dosing of tissue plasminogen activators. | Download Scientific Diagram
![Tenecteplase Improves Door‐to‐Needle Time in Real‐World Acute Stroke Treatment | Stroke: Vascular and Interventional Neurology Tenecteplase Improves Door‐to‐Needle Time in Real‐World Acute Stroke Treatment | Stroke: Vascular and Interventional Neurology](https://www.ahajournals.org/cms/asset/51e033dd-8672-4d0a-9115-3b39fe61d31a/svi212001-gra-0001.png)
Tenecteplase Improves Door‐to‐Needle Time in Real‐World Acute Stroke Treatment | Stroke: Vascular and Interventional Neurology
NursingCenter - Choosing the Correct “-ase” in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase http://ow.ly/cQGI50wZJ95 #RecommendedReading #Nurses #FOANed | Facebook
![The ENCHANTED Trial: Is Low-Dose the Right Dose for Intravenous tPA in Acute Ischemic Stroke? - REBEL EM - Emergency Medicine Blog The ENCHANTED Trial: Is Low-Dose the Right Dose for Intravenous tPA in Acute Ischemic Stroke? - REBEL EM - Emergency Medicine Blog](https://rebelem.com/wp-content/uploads/2016/05/The-ENCHANTED-Trial-Results-1024x340.png)
The ENCHANTED Trial: Is Low-Dose the Right Dose for Intravenous tPA in Acute Ischemic Stroke? - REBEL EM - Emergency Medicine Blog
![Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis | Scientific Reports Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-017-16355-9/MediaObjects/41598_2017_16355_Fig1_HTML.jpg)
Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis | Scientific Reports
![Comparison of Different Dosages of Alteplase in Atrial Fibrillation–Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan | Journal of the American Heart Association Comparison of Different Dosages of Alteplase in Atrial Fibrillation–Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/6ae3b592-31b5-4795-9279-b64fcb56d19e/jah37058-fig-0001.png)